Value of Biochemical Markers in the Management of Disseminated Prostatic Cancer

Pf, Mulders; P, Fernandez del Moral; Ag, Theeuwes; Go, Oosterhof; Ht, van Berkel; Fm, Debruyne

doi:10.1159/000474790

Cited by 25 publications

(12 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our result on time to PSA progression compares with findings on TTP previously reported, because it is estimated to take 6 to 12 months from PSA progression to the occurrence of radiologically detectable new lesions [28,29]. Our result on OS may be rather superior to previous reports [17,18] and the reason for that may be that 49% of the patients received docetaxel after failure to ADT in our study whereas few patients were treated with docetaxel in the past studies, though docetaxel treatment did not have a significant impact on OS in the present study.…”

Section: Discussionsupporting

confidence: 82%

Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy

Yamamoto¹,

Nozawa²,

Itami³

et al. 2013

J Cancer Res Ther

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy

Yamamoto¹,

Nozawa²,

Itami³

et al. 2013

J Cancer Res Ther

View full text Add to dashboard Cite

“…Furthermore, in patients with PD the elevation in the serum concentration of all markers evaluated in the present study con firms the notion that not only bone resorption but also bone formation is increased during the development of skeletal metastases. This can be demonstrated by the presence of mixed (osteolytic and osteoblastic) metastases, or by the attempt to maintain the 'coupling' of bone formation and resorption [13][14][15]. Our study seems to confirm the latter hypothesis since we did not find any difference in the basal val ues of the markers (except BGP) when the patients were divided according to the type of metastases.…”

Section: Discussionsupporting

confidence: 81%

Serum Markers of Bone Metastases in Postmenopausal Breast Cancer Patients Treated with Formestane

Martinetti

Bajetta²,

Seregni

et al. 1997

Tumor Biol

View full text Add to dashboard Cite

Bone metabolism marker evaluation is expected to play an auxiliary role in the diagnosis and follow-up of bone metastases in patients affected by different types of neoplasms. In this study we have evaluated osteoblastic and osteoclastic markers in 18 patients with bone metastases from breast cancer at diagnosis and for 1 year of follow-up during treatment with the aromatase inhibitor formestane. Osteoblastic markers include the carboxy-terminal propeptide of type I procol-lagen, the bone-specific alkaline phosphatase and the bone GLA protein. The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) was evaluated as a marker of osteoclastic activity. The patients were classified into three groups according to clinical response. A good correlation between marker level modifications and clinical evolution of skeletal metastases was observed for all the examined markers. Patients with progressive disease showed increasing levels of all markers, whereas patients in regression showed a reduction compared to the basal levels; patients with stable disease fell in between these two categories. We also found that basal ICTP values have prognostic significance: in the stable and progressive disease group they were higher than in the partial response group.

show abstract

“…Binding free energy (DG) and binding constants (K i ) were calculated and estimated within the AutoDock scoring function (Fig. 2) It is well known that the prostatic secretory protein PAP is often elevated in the sera of patients with prostate cancer (11)(12)(13)(14)(15). To determine the concentration of PAP required to hydrolyze 125 IQ 2-P to 125 IQ 2-OH , the SnQ 2-P -SnQ 2-P(I) mixture was incubated for z24 h in DMSO before its radioiodination, as this procedure has been shown to lead to the quantitative conversion of SnQ 2-P(I) to SnQ 2-P and the production of In vitro hydrolysis of 127 IQ 2-P / 125 IQ 2-P by human prostate tumor cells and normal mammalian cells assessed by fluorescence microscopy and autoradiography.…”

Section: Methodsmentioning

confidence: 99%

“…This hydrolase was selected because it is a phosphatase that is expressed and secreted exclusively by the prostate and overexpressed and abundantly secreted by prostate cancer cells (8)(9)(10). Consequently, serum levels of PAP are frequently elevated in patients and are used as a marker for the disease (11)(12)(13)(14)(15). Although PAP has never fully achieved the status of an indispensable frontline test among urologists, lymph node metastases and/or extensions (consequent to a breach of the prostate capsule) are invariably accompanied by a rise in serum PAP (15).…”

Section: Introductionmentioning

confidence: 99%

Computational Modeling and Experimental Evaluation of a Novel Prodrug for Targeting the Extracellular Space of Prostate Tumors

et al. 2007

View full text Add to dashboard Cite

We are developing a noninvasive approach for targeting imaging and therapeutic radionuclides to prostate cancer. Our method, Enzyme-Mediated Cancer Imaging and Therapy (EMCIT), aims to use enzyme-dependent, site-specific, in vivo precipitation of a radioactive molecule within the extracellular space of solid tumors. Advanced methods for data mining of the literature, protein databases, and knowledge bases (IT.Omics LSGraph and Ingenuity Systems) identified prostatic acid phosphatase (PAP) as an enzyme overexpressed in prostate cancer and secreted in the extracellular space. Using AutoDock 3.0 software, the prodrug ammonium 2-(2 ¶-phosphoryloxyphenyl)-6-iodo-4-(3H)-quinazolinone (IQ 2-P ) was docked in silico into the X-ray structure of PAP. The data indicate that IQ 2-P docked into the PAP active site with a calculated inhibition constant (K i ) more favorable than that of the PAP inhibitor A-benzylaminobenzylphosphonic acid. When 125 IQ 2-P , the radioiodinated form of the water-soluble prodrug, was incubated with PAP, rapid hydrolysis of the compound was observed as exemplified by formation of the water-insoluble 2-(2 ¶-hydroxyphenyl)-6-[125 I]iodo-4-(3H)-quinazolinone ( 125 IQ 2-OH ). Similarly, the incubation of IQ 2-P with human LNCaP, PC-3, and 22Rv1 prostate tumor cells resulted in the formation of large fluorescent IQ 2-OH crystals. No hydrolysis was seen in the presence of normal human cells. Autoradiography of tumor cells incubated with 125 IQ 2-P showed accumulation of radioactive grains ( 125 IQ 2-OH ) around the cells. We anticipate that the EMCIT approach will enable the active in vivo entrapment of radioimaging and radiotherapeutic compounds within the extracellular spaces of primary prostate tumors and their metastases. [Cancer Res 2007;67(5):2197-205]

show abstract

Value of Biochemical Markers in the Management of Disseminated Prostatic Cancer

Cited by 25 publications

References 13 publications

Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy

Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy

Serum Markers of Bone Metastases in Postmenopausal Breast Cancer Patients Treated with Formestane

Computational Modeling and Experimental Evaluation of a Novel Prodrug for Targeting the Extracellular Space of Prostate Tumors

Contact Info

Product

Resources

About